Clinical trial
Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S…
NCT00149084 · Hamamatsu University, Other · Unknown status
Key facts
| NCT number | NCT00149084 |
|---|---|
| Title | Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori |
| Official title | Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori |
| Lead sponsor | Hamamatsu University, Other |
| Collaborators | Yokoyama Foundation for Clinical Pharmacology |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Helicobacter Infections, Gastritis, Gastric Ulcer, Duodenal Ulcer |
| Intervention type | Drug |
| Interventions | Lansoprazole, clarithromycin, amoxicillin |
| Enrollment | 296 |
| Start date | Apr 1, 2003 |
| First posted | Sep 8, 2005 |
| Last update posted | Sep 11, 2006 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: